EGFR and glioblastoma: For this reason, cIMPACT-NOW Update 3 requires the detection of an EGFR amplification, a TERT promoter mutation or a complete gain of chromosome 7 combined with a complete deletion of chromosome 10, in addition to the two criteria ‘diffuse astrocytoma’ and ‘no IDH mutation’, in order to be able to establish the diagnosis ‘Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV’ [25].